Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New appointment at BioMedPartners

This article was originally published in Scrip

Executive Summary

The Swiss healthcare venture capital firm, BioMedPartners, has recruited Dr Andreas Schulze as a partner, and promoted Patrick Burgermeister to principal. Dr Schulze was previously CEO of the biotech company, Neurotune, and before that headed the biotech team at the German venture capital firm, DEWB. Mr Burgermeister joined BioMedPartners in 2006 from Novartis, where he was a senior portfolio manager.

You may also be interested in...



Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study

The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.

Pipeline Watch: Phase III Readouts For Cabotegravir, Filgotinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: ASCO Spotlights Anticancer Progress

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel